Expanded PD indication in Japan for Sumitomo's Trerief

3 July 2018

Japan’s Sumitomo Dainippon Pharma (TYO: 4506) has received approval in its home country for Trerief (zonisamide) as a treatment for parkinsonism in dementia with Lewy bodies (DLB).

First approved as a treatment for Parkinson’s disease (PD) in 2001, the product was launched in Japan in this indication in 2009, and the label was expanded in August 2013 to include extra dosing information for the treatment of PD patients experiencing wearing-off after treatment with the condition’s key therapy, levodopa.

The Osaka-based firm applied to the Japanese medicines regulator last year to include the DLB indication. The symptoms of parkinsonism in DLB are nearly the same as the symptoms of motor dysfunction in PD.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK